India Pharma Outlook Team | Thursday, 17 September 2026
A new MRI dye now promises to map tiny lung tumors and hidden metastases that current scans often miss.
Researchers tested a protein-based contrast agent that lights up lesions as small as one millimeter in animal studies.
The advance targets aggressive cancer features and could shift diagnosis to much earlier stages. Lung cancer usually reveals itself only after it spreads, which limits treatment choices.
This experimental dye works without radiation and may also show how aggressively a tumor is likely to behave. The findings open a fresh path for precision imaging that doctors have long needed.
Researchers at InLighta BioSciences developed the protein-based contrast agent called hProCA32.Collagen2. Animal studies showed that the agent identifies lung tumors and metastases measuring just one millimeter. The team published the results in Science Advances. Study leader Jenny Yang, founder and chief scientific officer of InLighta, explained the core problem: lung cancer often reaches diagnosis only after it has spread, when treatment options become more limited.
The imaging agent targets a structural protein called collagen type I. Aggressive lung tumors and metastatic lesions produce elevated levels of this protein. By locking onto collagen type I, the dye highlights both primary tumors and distant spread that standard methods struggle to catch early.
Yang stated that the technology can detect tiny tumors and hidden metastases without exposing patients to radiation. It also helps reveal how aggressive a cancer may be and how likely it is to spread. This capability could reduce the need for invasive biopsies.
Key advantages the researchers highlight include:
Also Read: How Can Indian Pharma Strengthen Quality Amid Rising FDA Scrutiny
The findings carry implications for personalized cancer treatment. The dye lets physicians observe collagen remodeling inside tumors. In this process, the body breaks down old or damaged collagen fibers and replaces them with newly organized proteins. Tracking these changes may help doctors identify high-risk patients, guide treatment selection, and monitor how well therapy works over time.
Yang called the advance a game changer for cancer diagnosis and precision medicine. She noted that the team has shown for the first time that precision MRI can detect tiny tumors and whole-body metastases without harmful radiation while also supplying important clues about how aggressively a cancer may behave.
The experimental agent remains under development. Its performance in animal models has generated clear interest because it addresses two longstanding gaps at once: finding lesions while they stay small and reading biological signals that signal future behavior. If further studies confirm the results in people, clinicians could gain a radiation-free tool that both maps disease earlier and informs treatment decisions more precisely.
